biostudies-literatureUnknown10(2)Blondeaux EMinistry of HealthF. Hoffmann-La RocheRoche Italia<h4>Background</h4>Estimating patient attrition across lines of treatment (i.e. the probability that upon treatment failure the patient will not be able to receive a subsequent treatment) may be a valuable tool for optimizing treatment sequencing. We sought to describe the first-to-second-line attrition rate and factors associated with attrition in a real-world cohort of patients with metastatic breast cancer.<h4>Methods</h4>The Gruppo Italiano Mammella (GIM)14/BIO-META (NCT02284581) is an ongoing, ambispective observational multicenter study enrolling patients with metastatic breast cancer receiving first-line therapy. In patients experiencing disease progression, attrition was defined as no further anticancer treatment and death within 6 months from the end of first-line therapy. The attESMO open104125https://www.ebi.ac.uk/biostudies/studies/S-EPMC11794064biostudies-literatureFactors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world.PMC11794064Ruelle TCaputo RDe Laurentiis MBlondeaux EDelucchi VPuglisi FDri ALambertini MChila GDel Mastro LGiannubilo IGeuna EBighin CPoggio FMontemurro FBoni LFabi APravisano FArpino GfalseFactors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world.<h4>Background</h4>Estimating patient attrition across lines of treatment (i.e. the probability that upon treatment failure the patient will not be able to receive a subsequent treatment) may be a valuable tool for optimizing treatment sequencing. We sought to describe the first-to-second-line attrition rate and factors associated with attrition in a real-world cohort of patients with metastatic breast cancer.<h4>Methods</h4>The Gruppo Italiano Mammella (GIM)14/BIO-META (NCT02284581) is an ongoing, ambispective observational multicenter study enrolling patients with metastatic breast cancer receiving first-line therapy. In patients experiencing disease progression, attrition was defined as no further anticancer treatment and death within 6 months from the end of first-line therapy. The att2025-01-01T00:00:00Z2025 Feb2026-06-02T18:27:00.316Z2025-04-04T00:06:29.392ZS-EPMC117940643984224510.1016/j.esmoop.2024.104125